Celltech Group (NYSE: CLL) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Celltech Group (NYSE: CLL)

An SI Board Since January 2000

Posts	SubjectMarks	Bans
123	10	0

Emcee: Tom Nealon	Type: Unmoderated

Introduction Compact

The Celltech group was created through the merger of Celltech Chiroscience (itself the result of a Celltech merger with Chiroscience) and Medeva and now trades (as of Jan. 26 2000) on the U.S. under the symbol CLL (it still trades in London as CCH). Medeva is something of a third rate company, but they had serious distribution and manufacturing capability to the combined company which now has capabilities in Gene discovery, target validation, chiral science, as well as Celltech's core antibody technology. Check out: biz.yahoo.com
for a rundown of the pipeline.

They haven't merged the three websites yet (bloody slow at doing that), so I'll post it as soon as they put them all together and update them.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
123	New CIMZIA (TM) Data from PRECiSE Program Reinforce Robust Efficacy in Once-Mont	nigel bates	-	5/22/2006
122	European filing for '870 in Crohn's - Message 22398975	nigel bates	-	4/28/2006
121	UCB to file CDP870 for rheumatoid arthritis in Dec 2006, Crohn's in Dec 2005	nigel bates	-	12/2/2004
120	UCB says positive results from phase 3 trial of Celltech's CDP-870 BRUSSELS	nigel bates	-	9/21/2004
119	I assume this is just arbitrage ? <pre>Celltech Group PLC 20 May 2004	nigel bates	-	5/20/2004
118	I dunno, I'd been happier if Chiroscience and OGS had never fallen into CLL.	keokalani'nui	-	5/19/2004
117	<i>I'd become so sick of it over the last few years...</i> Got	nigel bates	-	5/19/2004
116	No way would you disclose it...not if you want that position in the combined ent	keokalani'nui	-	5/19/2004
115	Dunno - I can't quite decide what to think about this one. What did tick me	nigel bates	-	5/19/2004
114	Thank heavens, a coup de gras. I'd become so sick of it over the last few y	keokalani'nui	-	5/18/2004
113	Belgium's UCB to buy UK's Celltech for 1.5 bln stg (Adds fund, more com	nigel bates	-	5/18/2004
112	Celltech Group plc Submits Xyrem for Approval in Europe Thursday April 1, 1:02 a	nigel bates	-	4/1/2004
111	Celltech Group plc Outlines Positive Preliminary Results From First CDP870 Phase	nigel bates	-	3/31/2004
110	Celltech Group plc -- Preliminary Announcement Of Results For Year Ended 31 Dece	nigel bates	-	3/16/2004
109	Celltech close to signing arthritis drug deal By Ben Hirschler, European Pharma	nigel bates	-	3/16/2004
108	This is still being ground through the mills of justice. Not sure how an adverse	nigel bates	-	2/16/2004
107	Celltech and Biogen Idec Announce Autoimmune Disease Collaboration Thursday Febr	nigel bates	-	2/5/2004
106	SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- Discovery Partners International, In	nigel bates	-	2/4/2004
105	Celltech Achieves Further Milestone In Osteoporosis Collaboration With Amgen S	nigel bates	-	1/8/2004
104	TEL AVIV, Jan 7 (Reuters) - Israel's Teva Pharmaceutical Industries said on	nigel bates	-	1/7/2004
103	Celltech Group plc Announces Initiation of CDP870 Phase III Trials in Crohn'	nigel bates	-	1/6/2004
102	ZURICH, Jan 5 (Reuters) - Swiss drug firm Actelion (Zurich:ATLN.S - News) said o	nigel bates	-	1/5/2004
101	Has slipped a bit, but Altana to file for approval of its PDE4 inhibitor in Febr	nigel bates	-	12/19/2003
100	Celltech Regains Full Rights To CDP 870 from Pfizer LONDON, Dec. 01, 2003 (PRI	nigel bates	-	12/1/2003
99	Celltech Group plc -- Closure of Seattle Research Facility SLOUGH, U.K., Nov. 1	nigel bates	-	11/19/2003

Go to reply# or date (mm/dd/yy):